{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:51:33Z","timestamp":1767847893189,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic glioma, characterized by large pleomorphic and frequently multinucleated cells, spindle and lipidized cells, a dense pericellular reticulin network, and numerous eosinophilic granular bodies according to the grade II glial tumor standards of the World Health Organization\u2019s (WHO) 2016 guidelines. PXA rarely transforms into anaplastic PXA or glioblastoma (GBM) and anaplastic PXA, classified as WHO grade III, has a more aggressive clinical behavior with poorer prognosis than PXA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Here we describe an unusual case of PXA in a 19-year-old woman, first admitted with headache and a mass in the left temporal lobe in 2005 that was removed. Twelve years later, she returned with left temporal headache, diplopia and tinnitus. A local tumor recurrence was found, and a second resection was performed. The specimen showed highly malignant findings, such as necrosis, microvascular proliferation, and multiple mitoses. The integrated diagnosis was made as high grade glioma, probably derived from PXA. Immunohistochemical (IHC) stains were positive for oligo2, and approximately 21% positive for Ki-67, while negative for CD34, IDH1 R132H. INI1 and ATRX were retained. As the histological classification was glioblastoma, the patient received GBM-appropriate chemotherapy and radiation therapy and outpatient follow-ups have demonstrated no obvious symptoms for 1\u2009year after surgery. Additional molecular analyses found BRAF V600E mutations in both resections, supporting the idea that the recurrent tumor had derived from PXA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case highlights the complexities of differential diagnosis based on the World Health Organization\u2019s 2016 guidelines. More integrated criteria to differentiate anaplastic PXA from GBM and epithelioid GBM, combined with genetic screening results, might be needed.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-020-1601-2","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T10:02:32Z","timestamp":1579082552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Noriyuki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Kohzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Zaboronok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"1601_CR1","first-page":"94","volume-title":"WHO classification of Tumours of the central nervous system","author":"C Giannini","year":"2016","unstructured":"Giannini C, Paulus W, Louis DN, Liberski PP, Figarella-Branger D, Capper D. Pleomorphic xanthoastrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of Tumours of the central nervous system, vol. 28-45. Lyon: International Agency for Research on Cancer (IARC); 2016. p. 94\u20139."},{"key":"1601_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.jocn.2014.04.002","volume":"21","author":"T Oh","year":"2014","unstructured":"Oh T, Kaur G, Madden M, Bloch O, Parsa AT. Pleomorphic xanthoastrocytomas: institutional experience of 18 patients. J Clin Neurosci. 2014;21:1767\u201372.","journal-title":"J Clin Neurosci"},{"key":"1601_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/bpa.12217","volume":"25","author":"CM Ida","year":"2015","unstructured":"Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, et al. Pleomorphic Xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25:575\u201386.","journal-title":"Brain Pathol"},{"key":"1601_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13000-016-0514-2","volume":"11","author":"SM Yamada","year":"2016","unstructured":"Yamada SM, Murakami H, Tomita Y, Nakane M, Shibui S, Takahashi M, et al. Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report. Diagn Pathol. 2016;11:65.","journal-title":"Diagn Pathol"},{"issue":"mar20 1","key":"1601_CR5","first-page":"bcr1220115372","volume":"2012","author":"F. Binesh","year":"2012","unstructured":"Binesh F, Akhavan A, Navabii H. Pleomorphic xanthoastrocytoma with malignant transformation and multiple recurrences in an Iranian girl. BMJ Case Rep. 2012;2012:bcr1220115372.","journal-title":"Case Reports"},{"key":"1601_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12957-015-0521-x","volume":"13","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Akahane T, Sawada T, Ikeda H, Tempaku A, Yamauchi S, et al. Adult classical glioblastoma with a BRAF V600E mutation. World J Surg Oncol. 2015;13:100.","journal-title":"World J Surg Oncol"},{"key":"1601_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bpa.12495","volume":"28","author":"RA Vaubel","year":"2018","unstructured":"Vaubel RA, Caron AA, Yamada S, Decker PA, Eckel Passow JE, Rodriguez FJ, et al. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol. 2018;28:172\u201382.","journal-title":"Brain Pathol"},{"key":"1601_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jocn.2011.07.015","volume":"19","author":"TM Vu","year":"2012","unstructured":"Vu TM, Liubinas SV, Gonzales M, Drummond KJ. Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci. 2012;19:12\u201320.","journal-title":"J Clin Neurosci"},{"key":"1601_CR9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4103\/ajns.AJNS_274_16","volume":"13","author":"N Singla","year":"2018","unstructured":"Singla N, Kapoor A, Radotra BD, Chatterjee D. Malignant conversion to Glioblastoma in Neurofibromatosis type I-associated pleomorphic Xanthoastrocytoma: unknown predictors of favorable outcome. Asian J Neurosurg. 2018;13:826\u20139.","journal-title":"Asian J Neurosurg"},{"key":"1601_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/neuonc\/not146","volume":"16","author":"S Dahiya","year":"2014","unstructured":"Dahiya S, Emnett RJ, Haydon DH, Leonard JR, Phillips JJ, Perry A, et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro-Oncology. 2014;16:318\u20139.","journal-title":"Neuro-Oncology"},{"key":"1601_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","volume":"126","author":"C Koelsche","year":"2013","unstructured":"Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126:907\u201315.","journal-title":"Acta Neuropathol"},{"key":"1601_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-DeMasters","year":"2013","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37:685\u201398.","journal-title":"Am J Surg Pathol"},{"key":"1601_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bpa.12572","volume":"28","author":"N Nakajima","year":"2018","unstructured":"Nakajima N, Nobusawa S, Nakata S, Nakada M, Yamazaki T, Matsumura N, et al. BRAF V600E, TERT promoter mutations and CDKN2A\/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. 2018;28:663\u201373.","journal-title":"Brain Pathol"},{"key":"1601_CR14","first-page":"2402","volume":"16","author":"Z Tosuner","year":"2018","unstructured":"Tosuner Z, Ge\u00e7er M\u00d6, Hatibo\u011flu MA, Abdallah A, Turna S. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncol Lett. 2018;16:2402\u20138.","journal-title":"Oncol Lett"},{"key":"1601_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10014-014-0192-2","volume":"31","author":"S Tanaka","year":"2014","unstructured":"Tanaka S, Nakada M, Nobusawa S, Suzuki SO, Sabit H, Miyashita K, et al. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol. 2014;31:172\u20136.","journal-title":"Brain Tumor Pathol"},{"key":"1601_CR16","first-page":"3291","volume":"38","author":"MC Burger","year":"2017","unstructured":"Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, et al. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep. 2017;38:3291\u20136.","journal-title":"Oncol Rep"},{"key":"1601_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/cns-2017-0006","volume":"6","author":"FB Nicholas","year":"2017","unstructured":"Nicholas FB, Thomas C, Nell K, Paul M. Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol. 2017;6:291\u20136.","journal-title":"CNS Oncol"},{"key":"1601_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fonc.2018.00526","volume":"8","author":"F Del Bufalo","year":"2018","unstructured":"Del Bufalo F, Ceglie G, Cacchione A, Alessi I, Colafati GS, Carai A, et al. BRAF V600E inhibitor (Vemurafenib) for BRAF V600E mutated low grade Gliomas. Front Oncol. 2018;8:526.","journal-title":"Front Oncol"},{"issue":"1","key":"1601_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cns-2016-0031","volume":"6","author":"Nicholas F Brown","year":"2017","unstructured":"Brown NF, Carter T, Mulholland P. Dabrafenib in BRAFV600mutated anaplastic pleomorphic xanthoastrocytoma. CNS Oncol. 2017;6:5\u20139.","journal-title":"CNS Oncology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-1601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-020-1601-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-1601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:25:38Z","timestamp":1665487538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-1601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-1601-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"9 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study has been performed in accordance with the Declaration of Helsinki. For case reports, ethics committee approval is not necessary at our organization. Informed consent was obtained from the patient included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}